Report cover image

Advanced Therapy Medicinal Products CDMO Market: Current Analysis and Forecast (2022-2028)

Publisher UnivDatos Market Insights
Published Feb 01, 2023
Length 149 Pages
SKU # Univ17823868

Description

Advanced Therapy Medicinal Products CDMO Market: Current Analysis and Forecast (2022-2028)

Advanced Therapy Medicinal Products (ATMPs) are a class of innovative medicinal products that include gene therapy, cell therapy, and tissue-engineered products. A CDMO, or Contract Development and Manufacturing Organization, is a company that provides services such as development, manufacturing, and quality control to support the production of ATMPs and other pharmaceutical products. The ATMP CDMO market is growing due to the increasing demand for ATMPs and the need for specialized manufacturing and development services for these complex products. As the ATMP market continues to expand, there is a high demand for CDMOs that can provide the necessary services and expertise to support the development and commercialization of ATMPs.

The Advanced Therapy Medicinal Products CDMO Market is expected to grow at a steady rate of around 14% owing to the increasing adoption of ATMPs while the demand for specialized CDMO services continues to increase. The growing demand for innovative treatments for various diseases, such as cancer and genetic disorders will drive the market growth. For instance, according to the data published by the American Cancer Society (ACS), in January 2020, around 1.8 million new cancer cases were diagnosed and 606,520 cancer deaths in the United States.
  • Based on product, the market is segmented into gene therapy, cell therapy, tissue engineering, and others. The gene therapy category is to witness a higher CAGR during the forecast period. This segment includes the production and manufacturing of viral and non-viral vectors for gene therapy, which are used to deliver therapeutic genes to target cells to treat various diseases. Major key players in this segment offer a range of services, including vector production, preclinical testing, and clinical trials for gene therapy products which will boost the growth of the market. For instance, in 2022, according to the American Society of Gene & Cell Therapy (ASGCT), around 1,986 gene therapy products, including CAR T-cell therapies and other genetically modified cell therapies are under development.
  • On the basis of phase, the market is categorized into phase I, phase II, phase III, and phase IV. Among these, phase I category held a significant share in the market in 2021. This is mainly due to growing R&D Initiatives and the rise in the number of advanced therapy human studies. For instance, according to the WHO, as of February 2022, around 671,228 clinical trials are ongoing globally, out of which 47,689 are under phase I clinical trials.
  • Based on indication, the advanced therapy medicinal products CDMO market has been classified into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, and others. The oncology category is to witness higher adoption of ATMP CDMO during the forecast period. This is mainly due to the growing number of patients with various types of cancer and an increasingly elderly population. For instance, according to the World Health Organization (WHO), there were an estimated 18.1 million new cases of cancer worldwide in 2020.
  • For a better understanding of the market adoption of the ATMP CDMO industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. this is mainly due to several factors, including the increasing demand for personalized medicine, the growing prevalence of chronic diseases, and the increasing investment in biotechnology research and development. The market is also driven by advancements in cell and gene therapy-related technologies, which are enabling the development of innovative treatments for rare diseases. For instance, as per an October 2021 update by the National Institutes of Health (NIH), USFDA, 10 pharmaceutical companies, and 5 non-profit organizations have partnered to accelerate the development of gene therapies for the 30 million Americans who suffer from a rare disease.
  • Some of the major players operating in the market include CELONIC Group; FUJIFILM Corporation; Bio Elpida; Rentschler Biopharma SE; AGC Biologics; Catalent, Inc; Lonza; WuXi AppTec Co., Ltd.; BlueReg; Thermo Fisher Scientific Inc.

Table of Contents

149 Pages
1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Process of the Advanced Therapy Medicinal Products CDMO Market
2.2. Research Methodology of the Advanced Therapy Medicinal Products CDMO Market
2.3. Respondent Profile
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 IMPACT OF COVID-19 ON THE Advanced Therapy Medicinal Products CDMO Market
6 Advanced Therapy Medicinal Products CDMO Market REVENUE, 2020-2028F
7 MARKET INSIGHTS BY PRODUCT
7.1. Gene Therapy
7.2. Cell Therapy
7.3. Tissue Engineered
7.4. Others
8 MARKET INSIGHTS BY PHASE
8.1. Phase I
8.2. Phase II
8.3. Phase III
8.4. Phase IV
9 MARKET INSIGHTS BY INDICATION
9.1. Oncology
9.2. Cardiology
9.3. Central Nervous System
9.4. Musculoskeletal
9.5. Infectious Disease
9.6. Others
10 MARKET INSIGHTS BY REGION
10.1. North America
10.1.1. U.S.
10.1.2. Canada
10.1.3. Rest of North America
10.2. Europe
10.2.1. Germany
10.2.2. U.K.
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Rest of Asia-Pacific
10.4. Rest of World
11 Advanced Therapy Medicinal Products CDMO Market DYNAMICS
11.1. Market Drivers
11.2. Market Challenges
11.3. Impact Analysis
12 Advanced Therapy Medicinal Products CDMO Market OPPORTUNITIES
13 Advanced Therapy Medicinal Products CDMO Market TRENDS
14 DEMAND AND SUPPLY-SIDE ANALYSIS
14.1. Demand Side Analysis
14.2. Supply Side Analysis
15 VALUE CHAIN ANALYSIS
16 PRICING ANALYSIS
17 STRATEGIC INSIGHTS
18 COMPETITIVE SCENARIO
18.1. Competitive Landscape
18.1.1. Porters Fiver Forces Analysis
19 COMPANY PROFILED
19.1. CELONIC Group
19.2. FUJIFILM Corporation
19.3. Bio Elpida
19.4. Rentschler Biopharma SE
19.5. AGC Biologics
19.6. Catalent, Inc
19.7. Lonza
19.8. WuXi AppTec Co., Ltd.
19.9. BlueReg
19.10. Thermo Fisher Scientific Inc.
20 DISCLAIMER

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us